Effect of Bifidobacterium bifidum fermented milk on Helicobacter pylori and serum pepsinogen levels in humans.
Helicobacter pylori infection is an important risk factor for gastric diseases. Some probiotics are useful for suppressing H. pylori infection. Bifidobacterium bifidum YIT 4007 can improve the experimental gastric injury in rats and the disease stages on the gastric mucosa in peptic ulcer patients. We evaluated the fermented milk using a clone (BF-1) having the stronger ability to survive in the product than this parent strain to clarify the in vitro suppressive effect of BF-1 on H. pylori and the in vivo efficacy of BF-1 fermented milk on H. pylori and gastric health. In the mixed culture assay of BF-1 and H. pylori, the number of pathogens was decreased such that it was not detected after 48 h in the Brucella broth with a decrease in pH values. In the cell culture experiment with human gastric cells, the H. pylori infection-induced IL-8 secretion was suppressed by the preincubation of BF-1. In a human study of 12-wk ingestion (BF-1 group, n = 40; placebo group, n = 39) with a randomized double-blind placebo-control design, the H. pylori urease activity and gastric situation were evaluated using a urea breath test (UBT) and the serum pepsinogen (PG) levels as biomarkers for inflammation or atrophy, respectively. In the H. pylori-positive subjects, the difference (DeltaUBT) of the UBT value from the baseline value in the BF-1 group (n = 34) was lower than that in the placebo group (n = 35) at 8 wk. The baseline UBT values showed a negative correlation with DeltaUBT values at 8 and 12 wk in the BF-1 group but not in the placebo. In the PG-positive subjects classified by the PG test method, the BF-1 group was lower in DeltaUBT values than the placebo group at 8 and 12 wk. In the active gastritis class by PG levels, the BF-1 group was lower in their DeltaUBT values than the placebo at 8 and 12 wk. The PG I levels in the BF-1 group were lower than the placebo at 12 wk. The PG II levels in the BF-1 group did not change during the ingestion period, but the placebo was increased. The PG I/II ratios slightly decreased from baseline at 12 and 20 wk in the BF-1 and placebo groups. These patterns were also observed in the H. pylori-positive subjects. The improving rates of upper gastrointestinal symptomatic subjects and total symptom numbers in the BF-1 group were higher than those in the placebo. These results indicate that BF-1 fermented milk may affect H. pylori infection or its activity, gastric mucosal situation, and the emergence of upper gastrointestinal symptoms.
Miki
K
K
Faculty of Medicine, Toho University, Ota-ku,Tokyo 143-8540, Japan.
Urita
Y
Y
Ishikawa
F
F
Iino
T
T
Shibahara-Sone
H
H
Akahoshi
R
R
Mizusawa
S
S
Nose
A
A
Nozaki
D
D
Hirano
K
K
Nonaka
C
C
Yokokura
T
T
D000818:Animals; D001644:Bifidobacterium / Q000502:physiology*; D015415:Biomarkers / Q000032:analysis / Q000097:blood; D001944:Breath Tests; D002460:Cell Line; D004311:Double-Blind Method; D005260:Female; D005285:Fermentation; D016481:Helicobacter Infections / Q000178:diet therapy*; D016480:Helicobacter pylori / Q000201:enzymology / Q000254:growth & development*; D006801:Humans; D016209:Interleukin-8 / Q000378:metabolism; D008297:Male; D008892:Milk / Q000382:microbiology*; D020116:Pepsinogen A / Q000097:blood*; D019936:Probiotics; D016896:Treatment Outcome; D014510:Urease / Q000378:metabolism
D015415:Biomarkers; D016209:Interleukin-8; D020116:Pepsinogen A; D014510:Urease